Use of 111In-bleomycin for combining radiotherapy and chemotherapy on glioma-bearing mice.
Mice bearing transplanted glioma received 0.9% NaCl, 0.1 mg of BLM, or 200-250 microCi of 111In-BLM (0.1 mg BLM) daily for 5 days intraperitoneally. After therapy, tumor sizes were in the order NaCl greater than BLM greater than 111In-BLM. On the 11th day after the first injection, tumor size (mm3) in the 111In-BLM group was 1,220; in the BLM group, it was 2,310 (P less than .025). After intratumor injection of a total dose of 0.1 mg of BLM/gm tumor weight, or of 1 mCi/gm tumor weight of 111In-BLM (carried by 0.1 mg of BLM/gm tumor weight), the tumor size decreased in the 111In-BLM group more than in the BLM group. On the 5th day after the 2nd dose therapy, the tumor size in the 111In-BLM group was 2,020; in the BLM group it was 4,220 (P less than .05). Host weights for these two groups were similar. The necrotic area in the tumor was much greater in the 111In-BLM group than in the BLM group. These results suggest the use for radiotherapy and chemotherapy.
D Y
DY
Hou
H
H
Hoch
G S
GS
Johnston
K C
KC
Tsou
R J
RJ
Farkas
E E
EE
Miller
D000230:Adenocarcinoma / Q000378:metabolism; D000818:Animals; D001761:Bleomycin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use* / Q000031:analogs & derivatives; D001918:Brachytherapy / Q000379:methods; D003131:Combined Modality Therapy; D004735:Energy Transfer; D005260:Female; D005910:Glioma / Q000473:pathology / Q000628:therapy*; D007204:Indium / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D007553:Isotope Labeling; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009942:Organometallic Compounds; D011868:Radioisotopes / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D051381:Rats; D014018:Tissue Distribution
D009942:Organometallic Compounds; D011868:Radioisotopes; C047120:indium-bleomycin; D007204:Indium; D001761:Bleomycin